ADMA Biologics, Inc. Files 2023 Annual Report on Form 10-K
Ticker: ADMA · Form: 10-K · Filed: Feb 28, 2024 · CIK: 1368514
| Field | Detail |
|---|---|
| Company | Adma Biologics, Inc. (ADMA) |
| Form Type | 10-K |
| Filed Date | Feb 28, 2024 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-K, ADMA Biologics, Annual Report, Biopharmaceutical, Financials
TL;DR
<b>ADMA Biologics, Inc. has filed its 2023 10-K annual report detailing its financial performance and business operations.</b>
AI Summary
ADMA BIOLOGICS, INC. (ADMA) filed a Annual Report (10-K) with the SEC on February 28, 2024. ADMA Biologics, Inc. filed its 10-K report for the fiscal year ending December 31, 2023. The company is incorporated in Delaware and its fiscal year ends on December 31st. Its principal business address is located at 465 State Route 17, Ramsey, NJ 07446. The filing is a Public Document with 90 pages. The SIC code for the company is 2836, Biological Products (No Diagnostic Substances).
Why It Matters
For investors and stakeholders tracking ADMA BIOLOGICS, INC., this filing contains several important signals. This 10-K filing provides a comprehensive overview of ADMA Biologics' financial health, operational activities, and strategic direction for the fiscal year 2023, which is crucial for investors to assess the company's performance and future prospects. Understanding the details within this filing is essential for stakeholders to evaluate the company's compliance with regulatory requirements and its position within the biological products industry.
Risk Assessment
Risk Level: medium — ADMA BIOLOGICS, INC. shows moderate risk based on this filing. The company's financial performance and future growth are subject to the inherent risks and uncertainties of the biopharmaceutical industry, including regulatory approvals, market competition, and product development timelines, as detailed in their 10-K filing.
Analyst Insight
Investors should review the detailed financial statements and risk factors in the 10-K to assess ADMA Biologics' long-term viability and growth potential.
Key Numbers
- 20231231 — Fiscal Year End (CONFORMED PERIOD OF REPORT)
- 20240228 — Filing Date (FILED AS OF DATE)
- 90 — Public Document Count (PUBLIC DOCUMENT COUNT)
- 2836 — SIC Code (STANDARD INDUSTRIAL CLASSIFICATION)
Key Players & Entities
- ADMA BIOLOGICS, INC. (company) — FILER
- 0001368514 (company) — CENTRAL INDEX KEY
- 2836 (company) — STANDARD INDUSTRIAL CLASSIFICATION
- DE (company) — STATE OF INCORPORATION
- 1231 (company) — FISCAL YEAR END
- 001-36728 (company) — SEC FILE NUMBER
- 465 STATE ROUTE 17 (company) — BUSINESS ADDRESS STREET 1
- RAMSEY (company) — BUSINESS ADDRESS CITY
FAQ
When did ADMA BIOLOGICS, INC. file this 10-K?
ADMA BIOLOGICS, INC. filed this Annual Report (10-K) with the SEC on February 28, 2024.
What is a 10-K filing?
A 10-K is a comprehensive annual financial report required by the SEC, covering audited financials, business operations, risk factors, and management discussion. This particular 10-K was filed by ADMA BIOLOGICS, INC. (ADMA).
Where can I read the original 10-K filing from ADMA BIOLOGICS, INC.?
You can access the original filing directly on the SEC's EDGAR system. The filing is publicly available and includes all exhibits and attachments submitted by ADMA BIOLOGICS, INC..
What are the key takeaways from ADMA BIOLOGICS, INC.'s 10-K?
ADMA BIOLOGICS, INC. filed this 10-K on February 28, 2024. Key takeaways: ADMA Biologics, Inc. filed its 10-K report for the fiscal year ending December 31, 2023.. The company is incorporated in Delaware and its fiscal year ends on December 31st.. Its principal business address is located at 465 State Route 17, Ramsey, NJ 07446..
Is ADMA BIOLOGICS, INC. a risky investment based on this filing?
Based on this 10-K, ADMA BIOLOGICS, INC. presents a moderate-risk profile. The company's financial performance and future growth are subject to the inherent risks and uncertainties of the biopharmaceutical industry, including regulatory approvals, market competition, and product development timelines, as detailed in their 10-K filing.
What should investors do after reading ADMA BIOLOGICS, INC.'s 10-K?
Investors should review the detailed financial statements and risk factors in the 10-K to assess ADMA Biologics' long-term viability and growth potential. The overall sentiment from this filing is neutral.
How does ADMA BIOLOGICS, INC. compare to its industry peers?
ADMA Biologics operates within the biopharmaceutical industry, focusing on the development, manufacturing, and commercialization of plasma-derived biologics.
Are there regulatory concerns for ADMA BIOLOGICS, INC.?
The company is subject to regulatory oversight by agencies such as the U.S. Food and Drug Administration (FDA) for its product development and manufacturing processes.
Industry Context
ADMA Biologics operates within the biopharmaceutical industry, focusing on the development, manufacturing, and commercialization of plasma-derived biologics.
Regulatory Implications
The company is subject to regulatory oversight by agencies such as the U.S. Food and Drug Administration (FDA) for its product development and manufacturing processes.
What Investors Should Do
- Review the financial statements for revenue, net income, and cash flow for FY 2023.
- Analyze the Management's Discussion and Analysis of Financial Condition and Results of Operations for insights into business performance.
- Examine the Risk Factors section for potential challenges and uncertainties facing the company.
Key Dates
- 2023-12-31: Fiscal Year End — Marks the end of the reporting period for the 10-K filing.
- 2024-02-28: Filing Date — Date the 10-K report was officially submitted to the SEC.
Year-Over-Year Comparison
This filing represents the annual report for the fiscal year 2023, providing updated financial and operational information compared to previous filings.
Filing Details
This Form 10-K (Form 10-K) was filed with the SEC on February 28, 2024 regarding ADMA BIOLOGICS, INC. (ADMA).